Drug Trial Radar · NCT03606967
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
86
Planned (sponsor's estimate)
Start
Apr 13, 2021
Primary completion
Dec 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jul 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel, durvalumab, and tremelimumab with or without neoantigen vaccine will work better in treating patients with triple negative breast cancer.
Conditions
- Anatomic Stage IV Breast Cancer AJCC v8
- Invasive Breast Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy ProcedureProcedure
Undergo tumor biopsy
Biospecimen CollectionProcedure
Undergo blood and urine sample collection
CarboplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT scan
DurvalumabBiological
Given IV
Gemcitabine HydrochlorideDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
Nab-paclitaxelDrug
Given IV
Personalized Synthetic Long Peptide VaccineBiological
Given SC
Poly ICLCDrug
Given SC
Sacituzumab GovitecanBiological
Given IV
TremelimumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: From initiation of Part B to progression or death, assessed at 6 and 12 months
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Active not recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Terminated
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut · Active not recruiting
Yale University
New Haven, Connecticut · Active not recruiting
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida · Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida · Recruiting
Moffitt Cancer Center-International Plaza
Tampa, Florida · Recruiting
Moffitt Cancer Center - McKinley Campus
Tampa, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Moffitt Cancer Center at Wesley Chapel
Wesley Chapel, Florida · Recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland · Recruiting
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri · Recruiting
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Siteman Cancer Center-South County
St Louis, Missouri · Recruiting
Siteman Cancer Center at Christian Hospital
St Louis, Missouri · Recruiting
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire · Suspended
NYP/Weill Cornell Medical Center
New York, New York · Recruiting
Wake Forest University at Clemmons
Clemmons, North Carolina · Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Active not recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
University of Texas Medical Branch
Galveston, Texas · Recruiting
VCU Massey Comprehensive Cancer Center
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.